Solagran reports Bioeffective R shows potential for use against cancer

New York, May 24 - Solagran Ltd. said that an initial trial showed Bioeffective R might be a potential anti-cancer treatment.

The investigation looked at an Ehrlich's carcinoma model in white mice and found that Bioeffective R stimulated production of natural interferon and helped maintain better structural integrity of the skin and cutaneous covering of the animals with the solid form of the carcinoma.

Compared to treatment with cyclophosphane, a commonly used - but toxic - chemotherapy drug, Bioeffective R at the lower dose tried inhibited growth of the carcinomas as well as cyclophosphane. The mortality rate during the 14-days was similar.

At the higher dose, Bioeffective R was less effective and appeared to stimulate tumor growth in the first six days. Mortality was similar to the control group.

Solagran also noted that Cyclophosphane suppressed interferon production.

Solagran is based in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.